Journal of Clinical Investigation 'Under Review': What the Status Means

The first status period is not the full scientific review. It is the journal checking whether the record can be handled: files open correctly, author metadata is complete, disclosures are included, ethics statements are present, and the manuscript appears to match the journal's scope. For Journal of Clinical Investigation, this stage matters because a small administrative issue can look like a peer-review delay from the author's side. If the status changes quickly to Under Review, read that as a routing signal, not as proof that every reviewer has accepted.

The useful action during this stage is not to ask whether the editor likes the paper. It is to make sure every status email, submission-form field, and manuscript file points to the same claim. A mismatch between the cover letter, abstract, figure sequence, and supplementary files creates editorial friction even when the science is credible. For JCI, the file package should make translational mechanism, disease relevance, and causal clinical evidence visible before a reviewer has to hunt for it.

At this point the manuscript is being read for fit. The editor is not only asking whether the manuscript is polished, but whether translational mechanism, disease relevance, and causal clinical evidence make the paper reviewable by the right people. In mechanistic clinical investigation, a manuscript can be technically competent and still difficult to route if the abstract promises one contribution while the methods, figures, or supplementary files support another.

The editor may be matching the manuscript to working physician-scientists and disease-mechanism reviewers who can test causality and clinical relevance. That matching process can take time because the editor needs reviewers who can evaluate the central claim without reconstructing the manuscript's logic from scratch. Under Review can therefore cover both reviewer recruitment and active review.

At Journal of Clinical Investigation, the handling editor is usually making two decisions at once: whether the submission deserves external review and which reviewer pool can test the manuscript fairly. That editorial culture matters because the status label can look static while the handling editor checks scope, article type, evidence traceability, conflicts, and reviewer availability. For JCI, Under Review is most useful when read as an editorial-routing state, not as a binary signal that the paper is safe. Authors should prepare for comments on translational mechanism, disease relevance, and causal clinical evidence while the handling editor is still shaping the review path.

In parallel, the editor may be identifying two or three reviewers and checking whether the manuscript has the right scope for those reviewers. Recruiting reviewers can take 7 to 21 days when the topic sits between fields, depends on a specialized dataset, or requires both methodological and domain expertise. A Journal of Clinical Investigation manuscript can therefore show Under Review while the editor is still securing the right reviewer mix.

For authors, the useful question is not "has someone accepted yet?" The useful question is "if a reviewer accepts today, would the manuscript's translational mechanism, disease relevance, and causal clinical evidence make the claim easy to evaluate?" That is the difference between passive waiting and productive waiting.

This is the main period in which reviewers evaluate the paper. They are usually checking whether the conclusion follows from the methods, whether the strongest comparison or control is present, whether figures match claims, and whether limitations are honest. In Journal of Clinical Investigation, the common weak point is a claim whose evidence package is present but not easy to audit.

Active review is also where timeline anxiety becomes least informative. A quiet portal does not tell you whether one reviewer is late, whether the editor is waiting for a second report, whether a reviewer declined and had to be replaced, or whether reports are already in synthesis. The strongest response is to prepare the material you will need under every plausible decision path.

After reports arrive, the editor has to turn them into a decision. This can still look like Under Review, Reviews Complete, Required Reviews Complete, or Decision in Process depending on the portal. Do not assume silence during this period means rejection. It can mean the editor is reconciling mixed reports, checking whether one reviewer misunderstood the scope, or deciding whether the manuscript needs another opinion.

The synthesis window is where the editor tests whether the reviewer concerns are compatible. If one reviewer wants deeper methods and another wants a shorter argument, the decision letter may take longer because the editor has to decide which instruction governs the revision. That delay is procedural, not necessarily negative.

Not automatically. The most common explanation is reviewer recruitment or a delayed report, not a hidden rejection. The more useful interpretation is whether the elapsed time matches the stage. If the paper moved to Under Review quickly and then stayed there, the editor may still be waiting on one reviewer. If the status changed after several weeks, the editor may be synthesizing reports. If there has been no movement past 12 weeks, a polite inquiry is reasonable.

What you should not do is rewrite the manuscript in panic or submit elsewhere. Prepare the response materials that will matter if the decision is revise, reject with comments, or transfer.

The pages that create the most avoidable status anxiety are not always the obviously weak papers. They are credible papers where authors wait passively during Under Review instead of preparing for the exact review objections most likely to arrive. Official guidance explains the workflow, but it rarely connects the status label to the manuscript components reviewers will test.

• JCI evidence-chain gap: In Journal of Clinical Investigation manuscripts, the editor needs to see translational mechanism, disease relevance, and causal clinical evidence without piecing together the claim from scattered files. Prepare a one-page response map that ties the central claim to figures, methods, data files, and limitations.

• JCI reviewer-routing risk: In Journal of Clinical Investigation manuscripts, the wrong reviewer pool can make a sound paper look less convincing than it is. Use the waiting window to identify how the abstract, keywords, suggested reviewers, and field framing point to working physician-scientists and disease-mechanism reviewers who can test causality and clinical relevance.

• JCI source-to-claim friction: In Journal of Clinical Investigation manuscripts, reviewers move quickly from headline claim to evidence traceability. Check that the source data, repository links, supplementary files, figure legends, and methods are easy to audit.

• JCI revision-readiness gap: In Journal of Clinical Investigation manuscripts, revision speed depends on whether authors already know which objection is likely. Draft answer blocks for the two most likely reviewer concerns before the decision letter arrives.

Risk 1: clinical language is layered onto a basic mechanism rather than driving the contribution. During Under Review, prepare a response note that separates what is already in the manuscript from what can be clarified in revision. That lets you answer a reviewer quickly without inflating the claim or adding unsupported language.

Risk 2: human evidence supports association but not causal disease relevance. During Under Review, prepare a response note that separates what is already in the manuscript from what can be clarified in revision. That lets you answer a reviewer quickly without inflating the claim or adding unsupported language.

Risk 3: animal, cellular, and patient data point in related but not identical directions. During Under Review, prepare a response note that separates what is already in the manuscript from what can be clarified in revision. That lets you answer a reviewer quickly without inflating the claim or adding unsupported language.

Risk 4: the paper belongs at JCI Insight or another translational journal rather than JCI flagship. During Under Review, prepare a response note that separates what is already in the manuscript from what can be clarified in revision. That lets you answer a reviewer quickly without inflating the claim or adding unsupported language.

Source limitation: JCI and the manuscript-submission portal are the authorities for active status. Manusights adds manuscript-risk interpretation from pre-submission review work, not access to private JCI editorial correspondence.

Decision in process usually means the editor has enough information to write or release a decision. It is not useful to email at that exact moment unless the journal requests action. Use the time to prepare three response paths: a clean revision response, a rejection-with-transfer plan, and a redirect plan if the decision says the manuscript is outside Journal of Clinical Investigation's fit.

Treat the revision as a reviewer-risk document, not just a marked manuscript. Build the response around reviewer comments, action taken, manuscript location, and evidence. If a reviewer misunderstood the work, answer with a clearer figure, paragraph, or table rather than only saying they misunderstood.

Do not waste the reviewer reports. Separate concerns into three groups: fatal journal-fit concerns, fixable presentation concerns, and evidence gaps that require new work. A rejection after Under Review can still be useful if it tells you whether the manuscript should be rebuilt for Journal of Clinical Investigation, transferred inside the publisher ecosystem, or moved to a better-matched venue.

Do not submit elsewhere. Do not send repeated status emails. Do not add new analyses to the submitted file unless the editor requests them. Do not assume that a quiet Under Review status means a negative decision. The productive action is to audit the abstract, methods, data availability statement, references, reporting frame, and likely reviewer objections.